论文部分内容阅读
Introduction. Cutaneous tolerance of the interferon beta used in the treatment of relapsing- remitting multiple sclerosis is good. However, among the rare adverse effects, vasculitis and glomerular impairment have been described for interferon beta- 1b. Case report. A 36- year- old woman had been given subcutaneous injections of interferon beta - 1a (Rebif , Serono) three times a week for ten weeks. A local transient cutaneous erythema was observed at the injection’ s sites. A few days after a new injection a erythematous plaques developed at the injection sites followed by pruritus, then purpura with edema on the leg in addition to an increase in body weight of 3kg. Biological data showed proteinuria and hematuria. The histology study of skin specimens suggested non- specific lymphocytic vasculitis. Outcome was favorable after discontinuing interferon beta- 1a. Conclusion. The etiology of the cutaneous and renal imparement is not formally established but the drug- induced hypothesis is proposed for interferon beta- 1a.
Introduction. Cutaneous tolerance of the interferon beta used in the treatment of relapsing- remitting multiple sclerosis is good. However, among the rare adverse effects, vasculitis and glomerular impairment have been described for interferon beta- 1b. Case report. A 36- year- old woman had been given subcutaneous injections of interferon beta - 1a (Rebif, Serono) three times a week for ten weeks. A local transient cutaneous erythema was observed at the injection ’s sites. A few days after a new injection a erythematous plaques developed at the injection sites followed by pruritus, then purpura with edema on the leg in addition to an increase in body weight of 3kg. The histology study of skin specimens suggested non-specific lymphocytic vasculitis. Outcome was favorable after discontinuing interferon beta-1a. Conclusion. The etiology of the cutaneous and renal imparement is not formally established but the drug-induced hypothe sis is proposed for interferon beta-1a.